BioNTech SE (22UA.F)

EUR 94.05

(4.04%)

Total Liabilities Summary of BioNTech SE

BioNTech SE's latest annual total liabilities in 2023 was 2.76 Billion EUR , down -14.37% from previous year.
BioNTech SE's latest quarterly total liabilities in 2024 Q1 was 2.29 Billion EUR , down -17.01% from previous quarter.
BioNTech SE reported annual total liabilities of 3.22 Billion EUR in 2022, down -18.13% from previous year.
BioNTech SE reported annual total liabilities of 3.93 Billion EUR in 2021, up 315.84% from previous year.
BioNTech SE reported quarterly total liabilities of 3.16 Billion EUR for 2024 Q2, up 38.27% from previous quarter.
BioNTech SE reported quarterly total liabilities of 2.34 Billion EUR for 2023 Q3, up 0.92% from previous quarter.

Annual Total Liabilities Chart of BioNTech SE (2023 - 2016)

Historical Annual Total Liabilities of BioNTech SE (2023 - 2016)

Year	Total Liabilities	Total Liabilities Growth
2023	2.76 Billion EUR	-14.37%
2022	3.22 Billion EUR	-18.13%
2021	3.93 Billion EUR	315.84%
2020	946.77 Million EUR	211.28%
2019	304.15 Million EUR	-21.2%
2018	385.98 Million EUR	-8.73%
2017	422.91 Million EUR	18.1%
2016	358.1 Million EUR	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q1	2.29 Billion EUR	-17.01%
2024 Q2	3.16 Billion EUR	38.27%
2023 Q3	2.34 Billion EUR	0.92%
2023 FY	2.76 Billion EUR	-14.37%
2023 Q2	2.31 Billion EUR	27.87%
2023 Q1	1.81 Billion EUR	-43.74%
2023 Q4	2.76 Billion EUR	17.95%
2022 Q4	3.22 Billion EUR	-24.94%
2022 FY	3.22 Billion EUR	-18.13%
2022 Q3	4.29 Billion EUR	-0.7%
2022 Q2	4.32 Billion EUR	-1.46%
2022 Q1	4.38 Billion EUR	11.48%
2021 Q4	3.93 Billion EUR	-28.69%
2021 Q1	1.68 Billion EUR	77.98%
2021 Q3	5.52 Billion EUR	50.6%
2021 Q2	3.66 Billion EUR	117.55%
2021 FY	3.93 Billion EUR	315.84%
2020 Q3	521.56 Million EUR	40.39%
2020 Q1	284.07 Million EUR	-6.6%
2020 FY	946.77 Million EUR	211.28%
2020 Q4	946.77 Million EUR	81.52%
2020 Q2	371.51 Million EUR	30.78%
2019 Q1	- EUR	-100.0%
2019 FY	304.15 Million EUR	-21.2%
2019 Q4	304.15 Million EUR	-5.54%
2019 Q2	337.87 Million EUR	0.0%
2019 Q3	322 Million EUR	-4.7%
2018 FY	385.98 Million EUR	-8.73%
2018 Q4	385.98 Million EUR	0.0%
2018 Q1	- EUR	0.0%
2017 FY	422.91 Million EUR	18.1%
2016 FY	358.1 Million EUR	0.0%

Peer Total Liabilities Comparison of BioNTech SE

Name	Total Liabilities	Total Liabilities Difference
CureVac N.V.	271.53 Million EUR	-916.603%
Biotest Aktiengesellschaft	945.4 Million EUR	-191.982%
Biotest Aktiengesellschaft	945.4 Million EUR	-191.982%
BRAIN Biotech AG	47.92 Million EUR	-5660.073%
Formycon AG	387.61 Million EUR	-612.157%
Heidelberg Pharma AG	21.01 Million EUR	-13036.483%
Medigene AG	10.65 Million EUR	-25819.249%